ANNOUNCEMENTS
This dissertation, "Evaluating ESG Framework Implementation and Climate Risk Resilience in the Pharmaceutical Sector," examines the application of sustainability reporting frameworks, climate risk assessments, and supply chain evaluation within a pharmaceutical manufacturing context. The research focuses on the implementation of the Business Responsibility and Sustainability Report (BRSR), Task Force on Climate-related Financial Disclosures (TCFD), and other global ESG frameworks across environmental, social, and governance dimensions.
The study involved on-site climate risk assessments at a pharmaceutical site in Gujarat to analyze exposure to physical climate hazards such as extreme heat, flooding, cyclones, and water scarcity. Scenario-based analysis using RCP 4.5 and RCP 8.5 projected climate risks for 2030 and 2050, while risk scoring matrices were applied to prioritize adaptation strategies across infrastructure, operations, workforce, and community impacts. High-risk hazards such as riverine floods and heat stress were identified as critical disruptors, demanding urgent mitigation investments.
Simultaneously, the research conducted a materiality assessment informed by stakeholder consultations and benchmarking against industry leaders (e.g., Cipla, Dr. Reddy’s, AstraZeneca), resulting in 18 key ESG focus areas. A detailed supply chain assessment was carried out using a digital platform, ESG-aligned vendor questionnaires, and gap analysis, culminating in Corrective and Preventive Action (CAPA) reports to drive supplier compliance and resilience.
The findings highlight the urgent need for ESG standardization, climate adaptation strategies, and supply chain transparency in the pharmaceutical sector. This study provides a replicable methodology for integrating climate risk analysis, ESG performance tracking, and stakeholder-informed materiality mapping to strengthen sustainable governance in pharmaceutical manufacturing.
